Nymox Pharmaceutical Corporation (NASDAQ:NYMX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

Shares of Nymox Pharmaceutical Corporation (NYMX) traded up 5.73% on Thursday, reaching $3.69. 234,698 shares of the company’s stock were exchanged. The firm’s 50-day moving average price is $3.75 and its 200 day moving average price is $3.84. The company has a market cap of $193.24 million, a price-to-earnings ratio of 11.18 and a beta of 0.84. Nymox Pharmaceutical Corporation has a 12 month low of $2.67 and a 12 month high of $5.10.

COPYRIGHT VIOLATION WARNING: “Nymox Pharmaceutical Corporation (NYMX) Lowered to Sell at ValuEngine” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/27/nymox-pharmaceutical-corporation-nymx-lowered-to-sell-at-valuengine.html.

In other news, Director James George Robinson acquired 15,000 shares of Nymox Pharmaceutical Corporation stock in a transaction that occurred on Wednesday, June 21st. The stock was bought at an average price of $3.77 per share, with a total value of $56,550.00. Following the completion of the purchase, the director now owns 3,008,150 shares in the company, valued at $11,340,725.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have purchased 152,500 shares of company stock valued at $583,370. 54.00% of the stock is owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System purchased a new position in shares of Nymox Pharmaceutical Corporation during the second quarter valued at approximately $222,000. State Street Corp purchased a new position in shares of Nymox Pharmaceutical Corporation during the second quarter valued at approximately $1,323,000. Goldman Sachs Group Inc. purchased a new position in shares of Nymox Pharmaceutical Corporation during the second quarter valued at approximately $117,000. Vanguard Group Inc. purchased a new position in shares of Nymox Pharmaceutical Corporation during the second quarter valued at approximately $302,000. Finally, Northern Trust Corp purchased a new position in shares of Nymox Pharmaceutical Corporation during the second quarter valued at approximately $199,000. 2.25% of the stock is owned by institutional investors.

Nymox Pharmaceutical Corporation Company Profile

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with MarketBeat.com's FREE daily email newsletter.